MAR 2014

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/276058

Contents of this Issue


Page 11 of 210

An advanced formulation of BROMDAY ® (bromfenac ophthalmic solution) 0.09% PROLENSA ® POWERED FOR PENETRATION Advanced formulation delivers corneal penetration 1-3 Proven efficacy at a lower concentration 1,4 PROLENSA ® delivers potency and penetration with QD efficacy 1,2 Available in 1.6-mL and 3-mL bottle sizes IMPORTANT RISK INFORMATION ABOUT PROLENSA ® Indications and Usage PROLENSA ® (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti- inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Dosage and Administration Instill one drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery, and through the first 14 days post surgery. Warnings and Precautions • Sulfite allergic reactions • Increased bleeding of ocular tissues • Slow or delayed healing • Corneal effects, including keratitis • Potential for cross-sensitivity • Contact lens wear Adverse Reactions The most commonly reported adverse reactions in 3%-8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and blurred vision. ®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates. ©2013 Bausch & Lomb Incorporated. Printed in USA US/PRA/13/0044(1)b 9/13 Please see brief summary of full Prescribing Information on adjacent page. References: 1. PROLENSA ® Prescribing Information, April 2013. 2. Data on file, Bausch & Lomb Incorporated. 3. Baklayan GA, Patterson HM, Song CK, Gow JA, McNamara TR. 24-hour evaluation of the ocular distribution of 14 C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits. J Ocul Pharmacol Ther. 2008;24(4):392-398. 4. BROMDAY ® Prescribing Information, October 2012.

Articles in this issue

Archives of this issue

view archives of Eyeworld - MAR 2014